DCTH · XBRL financial data

Delcath Systems financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DCTH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	3,555	2,719	2,065	37,205	85,231
Cost of revenue	640	671	686	635	6,188	11,797
Gross profit	1,006	2,884	2,033	1,430	31,017	73,434
Research and development	11,201	13,778	18,583	17,502	13,874	29,246
Selling, general and administrative	11,108	13,637	17,303	22,110	29,553	43,528
Total operating expenses	22,309	27,415	35,886	39,612	43,427	72,774
Operating income (loss)	(21,303)	(24,531)	(33,853)	(38,182)	(12,410)	660
Other income (expense)	154	68	30	(59)	(30)	(70)
Income tax expense (benefit)	0	0	0	0	0	810
Net income (loss)	(24,156)	(25,649)	(36,508)	(47,678)	(26,386)	2,700
Earnings per share, basic USD per share	(8.35)	(3.59)	(4.12)	(2.94)	(0.93)	0.08
Earnings per share, diluted USD per share	(8.35)	(3.59)	(4.12)	(2.94)	(0.93)	0.07
Weighted average shares, basic thousands of shares	2,898	7,146	8,865	16,230	28,511	35,821
Weighted average shares, diluted thousands of shares	2,898	7,146	8,865	16,230	28,511	39,920

Fiscal years (DCTH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	28,575	22,802	7,671	12,646	32,412	43,454
Marketable securities	—	—	0	19,808	20,821	47,582
Accounts receivable	57	44	366	241	10,890	11,744
Inventory	855	1,412	1,998	3,322	6,933	10,252
Prepaid and other current assets	2,670	2,743	1,969	1,091	2,704	6,498
Total current assets	32,338	31,152	16,155	37,158	73,760	119,530
Property and equipment, net	1,351	1,348	1,422	1,352	1,790	3,166
Right-of-use asset	946	624	285	103	1,039	936
Total assets	34,635	33,124	17,862	38,613	76,589	123,632
Accounts payable	1,774	638	2,018	1,012	961	2,658
Accrued liabilities	5,241	4,109	4,685	5,249	5,078	8,191
Total current liabilities	10,035	5,954	14,735	16,448	6,144	10,950
Lease liability, non-current	450	207	—	0	933	835
Total liabilities	12,557	21,172	23,721	22,836	7,843	12,413
Accumulated deficit	(395,327)	(420,976)	(457,484)	(505,162)	(531,548)	(528,848)
Total stockholders' equity	22,078	11,952	(5,859)	15,777	68,746	111,219
Total liabilities and equity	34,635	33,124	17,862	38,613	76,589	123,632
Common shares outstanding (cover page) thousands of shares	6,251	7,907	10,062	24,563	33,403	34,746

Fiscal years (DCTH's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(24,156)	(25,649)	(36,508)	(47,678)	(26,386)	2,700
Net cash from operating activities	(22,868)	(22,604)	(24,950)	(31,251)	(18,681)	22,516
Purchases of property and equipment	782	143	209	58	559	1,547
Net cash from investing activities	(782)	(143)	(209)	(19,709)	(981)	(26,590)
Proceeds from issuing common stock	230	2,458	0	123	250	481
Share repurchases	—	—	—	—	0	6,000
Repayments of long-term debt	—	—	714	6,313	10,600	—
Net cash from financing activities	42,355	20,822	10,143	51,778	39,410	15,048
Net change in cash	18,573	(1,803)	(15,131)	874	19,716	11,042

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Delcath Systems	47,521	29,133	5,712*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Ceribell	41,989	29,341	(13,078)*	38.8M	7.8 quarters	Q3 FY26 10-QSep 30, 2026
Axogen	328,888	75,834	16,536*	59.7M	—	Q3 FY26 10-QSep 30, 2026
Angiodynamics	33,973	80,915	(15,330)	42.1M	2.2 quarters	Q1 FY27 10-QAug 31, 2026
Orthofix Medical	103,810	210,933	(6,224)*	40.7M	16.7 quarters	Q2 FY26 10-QJun 30, 2026
Pulse Biosciences	101,620	434	(18,709)*	71.3M	5.4 quarters	Q2 FY26 10-QJun 30, 2026
Butterfly Network	122,301	32,598	(2,266)*	not reported	10.3 quarters	Q3 FY26 10-QSep 30, 2026
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Orthopediatrics	17,141	72,661	4,506*	26.1M	—	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.